US2003073694A1PendingUtilityA1

Antibiotic compositions and methods for using same

51
Assignee: ALLERGAN SALES INCPriority: Jul 30, 1999Filed: Jul 12, 2002Published: Apr 17, 2003
Est. expiryJul 30, 2019(expired)· nominal 20-yr term from priority
Inventors:Christopher A. MullerElizabeth A. BancroftJanet K. CheethamHarold G. JensenTeresa H. KuanDavid F. PowerKevin D. Skule
A61P 31/00A61P 27/02A61K 31/535A61K 31/50A61P 27/00A61K 9/0048
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions including a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, and a carrier component in an amount effective to act as a carrier for the quinolone component are provided. The present compositions are substantially free of other components effective as preservatives. Preferably the quinolone component has fungistatic activity. In one very useful embodiment, the compositions include a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A composition comprising: 
 a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye;    a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye; and    a carrier component in an amount effective to act as a carrier for the quinolone component and the NSAID component in the composition, the carrier component being ophthalmically acceptable, the composition being substantially free of other components effective as preservatives.    
     
     
         2 . The composition of  claim 1  wherein the NSAID component is a carboxyl group-containing NSAID component.  
     
     
         3 . The composition of  claim 1  wherein the carrier component is selected to provide the composition in a form selected from the group consisting of a solution, a suspension, a gel, an ointment and a solid.  
     
     
         4 . The composition of  claim 1  wherein the quinolone component is a halogenated quinolone component.  
     
     
         5 . The composition of  claim 4  wherein the NSAID component is a carboxyl group-containing NSAID component.  
     
     
         6 . The composition of  claim 1  wherein the quinolone component is a fluorinated quinolone component.  
     
     
         7 . The composition of  claim 6  wherein the NSAID component is a carboxyl group-containing NSAID component.  
     
     
         8 . The composition of  claim 1  wherein the quinolone component is an ofloxacin component  
     
     
         9 . The composition of  claim 8  wherein the NSAID component is a carboxyl group-containing NSAID component.  
     
     
         10 . The composition of  claim 1  wherein the NSAID component is a ketorolac component.  
     
     
         11 . The composition of  claim 10  wherein the carrier component is selected to provide the composition in a form selected from the group consisting of a solution, a suspension, a gel and an ointment.  
     
     
         12 . The composition of  claim 10  wherein the quinolone component is a halogenated quinolone component.  
     
     
         13 . The composition of  claim 10  wherein the quinolone component is a fluorinated quinolone component.  
     
     
         14 . The composition of  claim 10  wherein the quinolone component is an ofloxacin component  
     
     
         15 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 1 , thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.    
     
     
         16 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 3 , thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.    
     
     
         17 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 4 , thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.    
     
     
         18 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 8 , thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.    
     
     
         19 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 10 , thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.    
     
     
         20 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 14 , thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.    
     
     
         21 . A composition comprising: 
 a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, the quinolone component in the composition having fungistatic activity; and    a carrier component in an amount effective to act as a carrier for the quinolone component in the composition, the component being ophthalmically acceptable, the composition being substantially free of other components effective as preservatives.    
     
     
         22 . The composition of  claim 21  wherein the carrier component is selected to provide the composition in a form selected from the group consisting of a solution, a suspension, a gel, an ointment and a solid.  
     
     
         23 . The composition of  claim 21  wherein the quinolone component is a halogenated quinolone component.  
     
     
         24 . The composition of  claim 21  wherein the quinolone component is a fluorinated quinolone component.  
     
     
         25 . The composition of  claim 21  wherein the quinolone component is an ofloxacin component  
     
     
         26 . The composition of  claim 21  which further comprises an additional active component in an amount effective to provide a therapeutic effect when the composition is placed in a mammalian eye, the carrier component being effective to act as a carrier for the additional active component.  
     
     
         27 . The composition of  claim 26  wherein the additional active component is a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye.  
     
     
         28 . The composition of  claim 27  wherein the NSAID component is a carboxyl group containing NSAID component.  
     
     
         29 . The composition of  claim 27  wherein the NSAID component is a ketorolac component.  
     
     
         30 . The composition of  claim 29  wherein the quinolone component is an ofloxacin component.  
     
     
         31 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 21 .    
     
     
         32 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 22 .    
     
     
         33 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 25 .    
     
     
         34 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 29 .    
     
     
         35 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 30.

Join the waitlist — get patent alerts

Track US2003073694A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.